CDER Succession: Woodcock's Responsibilities Mount With No Clear #2 In Sight

If FDA decides to replace Richard Moscicki, that individual will almost automatically be seen as Janet Woodcock’s heir-apparent at CDER, should she choose to retire.

FDA entrance sign 2016

More from Agency Leadership

More from Pink Sheet